The United Kingdom and the United States have secured a significant trade agreement that will guarantee zero levies on British pharmaceutical products being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This commitment secures that import taxes on these crucial exports will remain at nothing for a duration of 36 months.
This development follows previous warnings to significantly raise duties on branded drug products, with figures floated reaching one hundred percent.
"This agreement with the United Kingdom strengthens the global environment for innovative medicines and establishes much-needed fairness to U.S.–U.K. medicine commerce," a release noted.
Commercial Importance
Pharmaceuticals constitute one of the UK's largest exports to the United States, which is easily the primary market for large UK drugmakers.
Trade data show that in the 12 months prior to last September, the UK exported drugs worth billions to the US. This amount represented 17.4% of all goods exports in that span.
"This deal secures work, increases investment and facilitates the UK to become a international leader for medical research," a minister commented.
Key British Pledges
The pact involves several specific changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments exceeded twenty percent.
Industry Background
The pact takes place against a long-running tension between the drug companies and the UK government over medicine costs and approval rates.
This friction were intensified by arguments that US patients were paying several times more for the identical medicines than people in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or cancelled, while major investments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
